High-Expenditure Disease in the EU-28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes?

BACKGROUND: Drug costs are increasing in Europe, and there is a heightened need to reduce pressure on healthcare systems. In 2017, oncology, autoimmune disease, and diabetes featured as the three highest therapy areas for drug spend in the EU-28. However, the absolute 1-year drug spend growth for di...

Descripción completa

Detalles Bibliográficos
Autores principales: Greiner, Wolfgang, Patel, Keyur, Crossman-Barnes, Christina-Jane, Rye-Andersen, Troels Vingtoft, Hvid, Christian, Vandebrouck, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333173/
https://www.ncbi.nlm.nih.gov/pubmed/33411314
http://dx.doi.org/10.1007/s41669-020-00253-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333173/
https://www.ncbi.nlm.nih.gov/pubmed/33411314
http://dx.doi.org/10.1007/s41669-020-00253-4

Ejemplares similares